Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
2017
Background
Recently, the need for maintenance chemotherapy arose as a result of the significantly improved survival of patients with metastatic colorectal cancer (mCRC) without increasing adverse events. Currently used maintenance regimens are fluoropyrimidines, bevacizumab, and the combination of fluoropyrimidine with bevacizumab. A new combination with bevacizumab and erlotinib, a tyrosine kinase inhibitor of the epithelial growth factor receptor, has shown synergistic effects in preclinical tests and promising results in some clinical trials. Whether bevacizumab combined with erlotinib vs. bevacizumab alone as maintenance therapy will further improve the clinical outcomes in patients with mCRC is controversial. We conducted this meta-analysis to compare the survival benefit and safety of these two regimens in patients with mCRC.
Keywords:
- Anesthesia
- Bevacizumab
- Epidermal growth factor receptor
- Erlotinib
- Colorectal cancer
- Cancer research
- Pharmacology
- Medicine
- Tyrosine-kinase inhibitor
- Maintenance therapy
- Chemotherapy
- Adverse effect
- Oncology
- Internal medicine
- Survival analysis
- Hazard ratio
- Randomized controlled trial
- Erlotinib Hydrochloride
- Clinical trial
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
38
References
6
Citations
NaN
KQI